(Q34491368)

2 August 2017

1 reference

title

High-density lipoprotein cholesterol and treatment guidelines (English)

1 reference

2 August 2017

0 references

Tonkin A

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

American Journal of Cardiology

2 August 2017

published in

1 reference

2 August 2017

volume

88

1 reference

2 August 2017

issue

12A

1 reference

2 August 2017

page(s)

41N-44N

1 reference

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902152-X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902152-X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902152-X

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902152-X

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902152-X

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902152-X

Management of hypertriglyceridemic patients. A. Treatment classifications and goals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902152-X

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902152-X

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902152-X

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902152-X

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902152-X

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902152-X

10.1016/S0002-9149(01)02152-X

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference